Last updated: September 1, 2026
Parsaclisib, Incyte's oral PI3K-delta inhibitor, is no longer an active commercial development program. Incyte discontinued clinical development in 2022 after the drug failed to establish a viable benefit-risk profile in myelofibrosis and faced increasing regulatory restrictions across the PI3K inhibitor class. Parsaclisib has no FDA approval, no Orange Book listing, no marketed revenue, and no disclosed commercial launch path.
The base-case market projection is therefore $0 in annual product sales. Any future value would depend on a licensing transaction, a reformulated development strategy, or new clinical evidence that changes the regulatory assessment.
What is parsaclisib and what was it designed to treat?
Parsaclisib, also known as INCB050465, is a selective oral inhibitor of phosphoinositide 3-kinase delta, or PI3K-delta. PI3K-delta is expressed predominantly in B cells, T cells, and other leukocytes, making it a target for B-cell malignancies and immune-mediated disease.
Incyte developed parsaclisib primarily for:
- Myelofibrosis, including combination treatment with ruxolitinib
- Follicular lymphoma
- Marginal zone lymphoma
- Diffuse large B-cell lymphoma
- Other B-cell non-Hodgkin lymphomas
The program was positioned against approved or late-stage PI3K-pathway drugs including idelalisib, duvelisib and umbralisib. The competitive thesis was based on improved selectivity, once-daily oral dosing and activity in patients who had received prior therapy.
Parsaclisib did not reach approval in any indication. Its development was also affected by class-wide concerns involving infections, immune-mediated toxicities, hepatotoxicity, colitis, pneumonitis and excess mortality observed with several PI3K inhibitors.
What is the current development status of parsaclisib?
Incyte discontinued parsaclisib development in 2022. The decision followed disappointing clinical results in the company's LIMBER and CITADEL programs and a deteriorating regulatory environment for PI3K inhibitors.
The most commercially important program was the combination of parsaclisib and ruxolitinib in myelofibrosis. The rationale was to improve spleen and symptom responses in patients whose disease was inadequately controlled by ruxolitinib alone. The Phase 3 LIMBER-304 study evaluated parsaclisib in combination with ruxolitinib in patients with myelofibrosis and suboptimal response to ruxolitinib.
The trial did not generate a sufficient clinical or commercial basis for continued development. Incyte subsequently removed parsaclisib from its active pipeline and stopped further investment in the program (Incyte, 2022; Incyte, 2023).
Parsaclisib development timeline
| Date |
Development event |
| 2010s |
Incyte advances parsaclisib as an oral PI3K-delta inhibitor |
| 2018-2020 |
Phase 2 CITADEL studies evaluate parsaclisib in B-cell malignancies |
| 2020-2021 |
LIMBER studies evaluate parsaclisib in myelofibrosis, including combinations with ruxolitinib |
| 2021 |
PI3K inhibitor safety concerns intensify after regulatory actions involving other class members |
| 2022 |
Incyte discontinues parsaclisib development |
| 2023 onward |
Parsaclisib is absent from Incyte's active commercial pipeline |
Why did Incyte discontinue parsaclisib?
The discontinuation reflected a combination of clinical, regulatory and commercial factors.
Myelofibrosis efficacy was insufficient
The parsaclisib-ruxolitinib strategy required a clinically meaningful improvement over ruxolitinib alone. The Phase 3 program did not produce the efficacy profile needed to support a high-probability registration strategy.
Myelofibrosis is a difficult market for new therapies because patients, physicians and regulators place substantial weight on spleen-volume reduction, symptom improvement, anemia management and overall survival. A combination that does not materially improve these outcomes has limited adoption potential even if it demonstrates biological activity.
PI3K-delta safety concerns increased development risk
The PI3K inhibitor class experienced regulatory setbacks because of:
- Serious and opportunistic infections
- Hepatotoxicity
- Severe diarrhea and colitis
- Pneumonitis
- Immune-mediated adverse events
- Treatment-related mortality signals in some randomized studies
The FDA required stronger safety controls and, in several cases, restricted or removed indications for PI3K inhibitors. These developments raised the evidence threshold for a new PI3K-delta product.
The competitive market became less attractive
Parsaclisib would have entered markets with established therapies and rapidly developing alternatives. In myelofibrosis, competition includes JAK inhibitors such as ruxolitinib, fedratinib, pacritinib and momelotinib. In B-cell lymphoma, the treatment landscape includes BTK inhibitors, BCL2-directed therapy, CAR-T therapy, bispecific antibodies and antibody-drug conjugates.
A PI3K-delta inhibitor therefore needed a clear advantage in efficacy, safety, sequencing or combination use. Parsaclisib did not demonstrate that advantage before development ended.
What is the FDA regulatory status of parsaclisib?
Parsaclisib has no FDA approval and has not received a New Drug Application approval. The drug has no approved indication, no FDA prescribing information and no commercial status in the United States.
There is no known FDA postmarketing safety program, Risk Evaluation and Mitigation Strategy or mandatory restricted distribution program for parsaclisib because the product never reached approval.
Regulatory status summary
| Regulatory item |
Parsaclisib status |
| FDA approval |
None |
| Approved indication |
None |
| NDA approval |
None publicly reported |
| Orange Book listing |
None |
| U.S. commercial launch |
None |
| FDA postmarketing commitments |
None |
| Biosimilar pathway |
Not applicable |
| Generic pathway |
Not commercially relevant without an approved reference product |
What patents protect parsaclisib?
Parsaclisib is protected, or was historically protected, by Incyte patent filings covering chemical compounds, pharmaceutical compositions, methods of treatment and potentially salt, polymorph and formulation claims.
Because parsaclisib never received FDA approval, there is no approved-product patent listing in the FDA Orange Book. This distinction matters. Orange Book-listed patents are generally tied to approved drug products and can support statutory certification procedures for abbreviated new drug applications. A development-stage compound can still have substantial patent protection, but those rights are not presented as an Orange Book product estate.
Patent categories associated with the program
| Patent category |
Commercial relevance |
| Composition-of-matter claims |
Primary protection for the parsaclisib chemical structure |
| Pharmaceutical composition claims |
Protection for drug products containing parsaclisib |
| Method-of-treatment claims |
Potential protection for lymphoma or myelofibrosis treatment |
| Combination claims |
Potential protection for use with ruxolitinib or other agents |
| Manufacturing claims |
Possible protection for synthesis or intermediates |
| Formulation claims |
Potential protection for oral dosage forms |
Public disclosures do not establish an active Orange Book patent challenge because no FDA-approved parsaclisib product exists. There is also no established Paragraph IV litigation pathway for a commercial generic version of parsaclisib.
When does parsaclisib lose exclusivity?
There is no commercially operative exclusivity date because parsaclisib never obtained FDA approval. Patent expiration dates for individual Incyte families may extend beyond the program's clinical discontinuation, but patent existence does not create market exclusivity in the absence of an approved product.
The key distinction is between:
- Patent term, which can continue after clinical development ends.
- Regulatory exclusivity, which generally depends on FDA approval.
- Commercial exclusivity, which requires an approved and marketable product.
Parsaclisib has no FDA new chemical entity exclusivity, orphan-drug exclusivity or Orange Book-linked exclusivity period.
Are there Paragraph IV challenges or generic entry risks?
No meaningful Paragraph IV challenge has been publicly associated with parsaclisib. The absence of a reference-listed drug, FDA approval and commercial sales removes the conventional incentive for a generic manufacturer to file an ANDA.
Generic entry risk is therefore not the principal issue. The more relevant risk is asset abandonment. If Incyte retains enforceable patents, the company could still control development rights in certain jurisdictions. If patents have expired or are no longer maintained, third parties could potentially study or commercialize a product only after addressing regulatory requirements and any surviving patent claims.
A future developer would also face the need to generate new clinical data. Parsaclisib cannot rely on the market position of an approved reference product because it never obtained that status.
What formulations and methods of use were being developed?
Parsaclisib was developed as an oral small-molecule therapy. Public clinical programs focused on systemic treatment rather than a specialized delivery system.
The principal method-of-use strategies included:
- Treatment of relapsed or refractory B-cell malignancies
- Treatment of follicular lymphoma after prior therapy
- Treatment of marginal zone lymphoma
- Treatment of diffuse large B-cell lymphoma
- Combination treatment with ruxolitinib in myelofibrosis
- Use in patients with inadequate response to prior therapy
The combination with ruxolitinib was the most important formulation-independent commercial strategy. It sought to expand the value of an existing JAK inhibitor by adding PI3K-delta pathway inhibition. The failure of this approach materially reduced the development rationale for the asset.
Which companies were competing with parsaclisib?
Parsaclisib competed against both direct PI3K inhibitors and broader targeted therapies.
| Company |
Product or class |
Relevant competitive position |
| Gilead Sciences |
Idelalisib |
First-in-class PI3K-delta inhibitor; approved in selected hematologic malignancies |
| Secura Bio |
Duvelisib |
PI3K-delta/gamma inhibitor for relapsed hematologic malignancies |
| TG Therapeutics |
Umbralisib |
PI3K-delta/CK1-epsilon inhibitor; later withdrawn from the U.S. market |
| Novartis |
Tisagenlecleucel |
CAR-T therapy competing in relapsed B-cell malignancies |
| Bristol Myers Squibb |
Lisocabtagene maraleucel |
CAR-T therapy for B-cell lymphoma |
| AbbVie and Genentech |
Venetoclax-based regimens |
BCL2-directed treatment in selected hematologic cancers |
| BeiGene |
Zanubrutinib |
BTK inhibitor competing in B-cell malignancies |
| AstraZeneca |
Acalabrutinib |
BTK inhibitor used across B-cell cancers |
| Incyte |
Ruxolitinib |
Existing JAK inhibitor and intended combination partner in myelofibrosis |
The competitive pressure was strongest in lymphoma, where cellular therapy, bispecific antibodies and BTK inhibitors have expanded treatment options. In myelofibrosis, treatment decisions are driven by anemia, thrombocytopenia, spleen symptoms and survival, limiting the opportunity for a drug with an unproven incremental benefit.
What is the commercial market projection for parsaclisib?
Parsaclisib has no current commercial market because it is not approved or marketed. The base-case forecast is:
| Metric |
Projection |
| Current U.S. product revenue |
$0 |
| Current global product revenue |
$0 |
| FDA-approved indications |
0 |
| Active commercial partnerships publicly disclosed |
None identified |
| Near-term launch probability |
Very low |
| Generic erosion risk |
Not applicable |
| Value of any future program |
Dependent on licensing and new clinical validation |
A relaunch would require a new sponsor to fund clinical development, establish a differentiated indication and overcome the safety concerns associated with the PI3K class. The most plausible routes would be:
- A biomarker-defined lymphoma population with high unmet need.
- A combination regimen with a clearly measurable benefit over standard therapy.
- A reformulated or altered dosing approach that improves safety.
- A non-oncology indication supported by a new mechanism-based clinical rationale.
None of these routes had produced a disclosed active program through the latest public Incyte pipeline disclosures.
How strong is the parsaclisib patent estate?
The patent estate was strategically meaningful during active development because composition-of-matter and treatment claims could have protected a future product. Its current commercial strength is lower because the development program ended before approval.
Patent strength should be assessed across four dimensions:
- Remaining term of composition-of-matter patents
- Geographic maintenance and prosecution status
- Claim scope covering parsaclisib itself rather than broad genus compounds
- Freedom to operate around combinations, salts, polymorphs and manufacturing processes
The lack of an Orange Book listing does not mean that all patent protection has disappeared. It means that no approved parsaclisib product currently anchors an Orange Book patent dispute or generic substitution pathway.
What litigation or licensing deals affect parsaclisib?
No major publicly disclosed patent litigation, Paragraph IV settlement or commercial licensing transaction has established a market for parsaclisib.
Incyte was the principal developer and patent holder associated with the asset. The program's discontinuation reduced the likelihood of near-term licensing activity, although abandoned or paused oncology assets can be licensed when a buyer sees value in a narrow indication or combination strategy.
The absence of a disclosed license, co-development agreement or settlement means there is no established external commercialization partner to support a launch forecast.
What generic launch scenarios exist for parsaclisib?
A conventional generic launch is unlikely in the foreseeable term because:
- No FDA-approved reference product exists.
- No Orange Book-listed parsaclisib product exists.
- No commercial prescription market has been established.
- Clinical and regulatory development would still be required.
- PI3K inhibitor safety concerns would complicate substitution economics.
A future sponsor could develop parsaclisib as a 505(b)(2) or full NDA product depending on the proposed use and available data, but such a strategy would not resemble a routine ANDA launch. It would require a new regulatory and clinical plan.
Key Takeaways
- Parsaclisib is an unapproved oral PI3K-delta inhibitor formerly developed by Incyte.
- Incyte discontinued the program in 2022.
- The central development strategy was parsaclisib plus ruxolitinib in myelofibrosis.
- No FDA approval, Orange Book listing, commercial launch or product revenue exists.
- No meaningful Paragraph IV or generic-entry pathway is established.
- Patent rights may remain in individual jurisdictions, but they do not create active product exclusivity without approval.
- The base-case commercial forecast is $0.
- Any residual asset value depends on a new sponsor, a differentiated indication and a successful strategy to address PI3K-class safety concerns.
FAQs About Parsaclisib
Is parsaclisib approved by the FDA?
No. Parsaclisib has no FDA-approved indication and has never been commercially launched in the United States.
Did parsaclisib fail in myelofibrosis?
The parsaclisib-ruxolitinib development strategy did not produce a sufficient basis for continued Phase 3 development. Incyte discontinued the program in 2022.
Is parsaclisib the same as idelalisib?
No. Both are PI3K-delta inhibitors, but parsaclisib and idelalisib are different chemical entities developed by different programs. Idelalisib reached FDA approval; parsaclisib did not.
Can a generic company launch parsaclisib?
There is no conventional generic launch pathway because parsaclisib lacks an FDA-approved reference-listed drug and an Orange Book product listing.
Could parsaclisib be licensed to another oncology company?
A license is theoretically possible, but no major public licensing transaction has established a current commercial development program. A buyer would need to reassess efficacy, safety, patent life and regulatory feasibility.
References
- Incyte Corporation. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2021.
- Incyte Corporation. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022.
- ClinicalTrials.gov. (n.d.). Study of parsaclisib in participants with myelofibrosis who have suboptimal response to ruxolitinib: LIMBER-304. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (2022). FDA and industry actions addressing safety concerns with PI3K inhibitors.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
